Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

UHS vs THC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
UHS
Universal Health Services, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$10.68B
5Y Perf.+61.7%
THC
Tenet Healthcare Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$17.01B
5Y Perf.+792.1%

UHS vs THC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
UHS logoUHS
THC logoTHC
IndustryMedical - Care FacilitiesMedical - Care Facilities
Market Cap$10.68B$17.01B
Revenue (TTM)$17.76B$21.45B
Net Income (TTM)$1.52B$1.70B
Gross Margin67.6%42.8%
Operating Margin11.5%16.1%
Forward P/E7.3x10.9x
Total Debt$5.51B$13.17B
Cash & Equiv.$138M$2.88B

UHS vs THCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

UHS
THC
StockMay 20May 26Return
Universal Health Se… (UHS)100161.7+61.7%
Tenet Healthcare Co… (THC)100892.1+792.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: UHS vs THC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: UHS leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Tenet Healthcare Corporation is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
UHS
Universal Health Services, Inc.
The Income Pick

UHS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.60, yield 0.5%
  • Rev growth 9.7%, EPS growth 37.3%, 3Y rev CAGR 9.0%
  • Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
Best for: income & stability and growth exposure
THC
Tenet Healthcare Corporation
The Long-Run Compounder

THC is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 5.2% 10Y total return vs UHS's 30.8%
  • PEG 0.33 vs UHS's 0.46
  • PEG 0.33 vs 0.46
Best for: long-term compounding and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthUHS logoUHS9.7% revenue growth vs THC's 3.1%
ValueTHC logoTHCPEG 0.33 vs 0.46
Quality / MarginsUHS logoUHS8.6% margin vs THC's 7.9%
Stability / SafetyUHS logoUHSBeta 0.60 vs THC's 0.71, lower leverage
DividendsUHS logoUHS0.5% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)THC logoTHC+27.4% vs UHS's -8.2%
Efficiency (ROA)UHS logoUHS9.8% ROA vs THC's 5.7%, ROIC 12.3% vs 13.2%

UHS vs THC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

UHSUniversal Health Services, Inc.
FY 2025
Acute Care Hospital Services
57.2%$9.9B
Behavioral Health Services
42.8%$7.4B
THCTenet Healthcare Corporation
FY 2025
Ambulatory Care
50.2%$5.2B
Hospital Operations
49.8%$5.1B

UHS vs THC — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLUHSLAGGINGTHC

Income & Cash Flow (Last 12 Months)

Evenly matched — UHS and THC each lead in 3 of 6 comparable metrics.

THC and UHS operate at a comparable scale, with $21.5B and $17.8B in trailing revenue. Profitability is closely matched — net margins range from 8.6% (UHS) to 7.9% (THC). On growth, UHS holds the edge at +9.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
RevenueTrailing 12 months$17.8B$21.5B
EBITDAEarnings before interest/tax$2.7B$4.3B
Net IncomeAfter-tax profit$1.5B$1.7B
Free Cash FlowCash after capex$894M$3.3B
Gross MarginGross profit ÷ Revenue+67.6%+42.8%
Operating MarginEBIT ÷ Revenue+11.5%+16.1%
Net MarginNet income ÷ Revenue+8.6%+7.9%
FCF MarginFCF ÷ Revenue+5.0%+15.6%
Rev. Growth (YoY)Latest quarter vs prior year+9.6%+2.8%
EPS Growth (YoY)Latest quarter vs prior year+17.7%+87.6%
Evenly matched — UHS and THC each lead in 3 of 6 comparable metrics.

Valuation Metrics

UHS leads this category, winning 5 of 7 comparable metrics.

At 7.4x trailing earnings, UHS trades at a 41% valuation discount to THC's 12.5x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs UHS's 0.46x — a lower PEG means you pay less per unit of expected earnings growth.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
Market CapShares × price$10.7B$17.0B
Enterprise ValueMkt cap + debt − cash$16.0B$27.3B
Trailing P/EPrice ÷ TTM EPS7.38x12.53x
Forward P/EPrice ÷ next-FY EPS est.7.30x10.94x
PEG RatioP/E ÷ EPS growth rate0.46x0.38x
EV / EBITDAEnterprise value multiple6.14x6.34x
Price / SalesMarket cap ÷ Revenue0.61x0.80x
Price / BookPrice ÷ Book value/share1.48x1.97x
Price / FCFMarket cap ÷ FCF12.57x6.72x
UHS leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

UHS leads this category, winning 7 of 9 comparable metrics.

UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $20 for THC. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), THC scores 7/9 vs UHS's 6/9, reflecting strong financial health.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
ROE (TTM)Return on equity+20.7%+19.6%
ROA (TTM)Return on assets+9.8%+5.7%
ROICReturn on invested capital+12.3%+13.2%
ROCEReturn on capital employed+16.0%+13.8%
Piotroski ScoreFundamental quality 0–967
Debt / EquityFinancial leverage0.74x1.47x
Net DebtTotal debt minus cash$5.4B$10.3B
Cash & Equiv.Liquid assets$138M$2.9B
Total DebtShort + long-term debt$5.5B$13.2B
Interest CoverageEBIT ÷ Interest expense10.92x4.28x
UHS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

THC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $11,248 for UHS. Over the past 12 months, THC leads with a +27.4% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs UHS's 6.5% — a key indicator of consistent wealth creation.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
YTD ReturnYear-to-date-22.3%-2.7%
1-Year ReturnPast 12 months-8.2%+27.4%
3-Year ReturnCumulative with dividends+20.8%+178.5%
5-Year ReturnCumulative with dividends+12.5%+190.4%
10-Year ReturnCumulative with dividends+30.8%+523.4%
CAGR (3Y)Annualised 3-year return+6.5%+40.7%
THC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — UHS and THC each lead in 1 of 2 comparable metrics.

UHS is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than THC's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 78.5% from its 52-week high vs UHS's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
Beta (5Y)Sensitivity to S&P 5000.60x0.71x
52-Week HighHighest price in past year$246.33$247.21
52-Week LowLowest price in past year$152.33$146.60
% of 52W HighCurrent price vs 52-week peak+69.2%+78.5%
RSI (14)Momentum oscillator 0–10039.752.9
Avg Volume (50D)Average daily shares traded793K1.2M
Evenly matched — UHS and THC each lead in 1 of 2 comparable metrics.

Analyst Outlook

UHS leads this category, winning 1 of 1 comparable metric.

Wall Street rates UHS as "Hold" and THC as "Buy". Consensus price targets imply 38.1% upside for THC (target: $268) vs 35.7% for UHS (target: $232). UHS is the only dividend payer here at 0.47% yield — a key consideration for income-focused portfolios.

MetricUHS logoUHSUniversal Health …THC logoTHCTenet Healthcare …
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$231.50$268.00
# AnalystsCovering analysts4332
Dividend YieldAnnual dividend ÷ price+0.5%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$0.80
Buyback YieldShare repurchases ÷ mkt cap+9.1%+8.4%
UHS leads this category, winning 1 of 1 comparable metric.
Key Takeaway

UHS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). THC leads in 1 (Total Returns). 2 tied.

Best OverallUniversal Health Services, … (UHS)Leads 3 of 6 categories
Loading custom metrics...

UHS vs THC: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is UHS or THC a better buy right now?

For growth investors, Universal Health Services, Inc.

(UHS) is the stronger pick with 9. 7% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Tenet Healthcare Corporation (THC) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — UHS or THC?

On trailing P/E, Universal Health Services, Inc.

(UHS) is the cheapest at 7. 4x versus Tenet Healthcare Corporation at 12. 5x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus Universal Health Services, Inc. 's 0. 46x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — UHS or THC?

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.

4%, compared to +12. 5% for Universal Health Services, Inc. (UHS). Over 10 years, the gap is even starker: THC returned +523. 4% versus UHS's +30. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — UHS or THC?

By beta (market sensitivity over 5 years), Universal Health Services, Inc.

(UHS) is the lower-risk stock at 0. 60β versus Tenet Healthcare Corporation's 0. 71β — meaning THC is approximately 17% more volatile than UHS relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — UHS or THC?

By revenue growth (latest reported year), Universal Health Services, Inc.

(UHS) is pulling ahead at 9. 7% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, UHS leads at 9. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — UHS or THC?

Universal Health Services, Inc.

(UHS) is the more profitable company, earning 8. 6% net margin versus 6. 6% for Tenet Healthcare Corporation — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus 11. 5% for UHS. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is UHS or THC more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus Universal Health Services, Inc. 's 0. 46x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 10. 9x for Tenet Healthcare Corporation — 3. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 38. 1% to $268. 00.

08

Which pays a better dividend — UHS or THC?

In this comparison, UHS (0.

5% yield) pays a dividend. THC does not pay a meaningful dividend and should not be held primarily for income.

09

Is UHS or THC better for a retirement portfolio?

For long-horizon retirement investors, Tenet Healthcare Corporation (THC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), +523. 4% 10Y return). Both have compounded well over 10 years (THC: +523. 4%, UHS: +30. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between UHS and THC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

UHS

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

THC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform UHS and THC on the metrics below

Revenue Growth>
%
(UHS: 9.6% · THC: 2.8%)
Net Margin>
%
(UHS: 8.6% · THC: 7.9%)
P/E Ratio<
x
(UHS: 7.4x · THC: 12.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.